CatalystWireBeta

CAP accreditation

In brief · summary, not quotable

No summary for this filing – the full text is below.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your VRCI notes

Verici Dx (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that its testing laboratory in Franklin, TN, has been accredited by the internationally recognised College of American Pathology (CAP) following the completion of an on-site audit. The Company, whose clinical laboratory is already CLIA certified, voluntarily sought the accreditation as part of its on-going commitment to maintaining best in class quality systems.

CAP accreditation is a hallmark of quality and excellence in clinical laboratory services and adds to the Company's existing portfolio of quality assurance awards and recognition.

In achieving the CAP accreditation requirements, which often exceed the standards from CLIA, FDA and OSHA, Verici Dx exhibits focus on excellence in patient care and laboratory safety. It also further demonstrates the laboratory's ability to deliver reliable and accurate test results to support patient clinical management.

Patti Connolly, Chief Operating Officer at Verici Dx, said: "We are pleased that our highly skilled laboratory team successfully achieved this accreditation with no deficiencies, findings, or recommendations identified during the audit. This accomplishment affirms our commitment to operating at the highest standards that healthcare providers, patients, and regulatory bodies expect."

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note